

CORRECTION

Open Access



Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients

Bin Zhao^{1*}, Hong Zhao^{2*} and Jiaxin Zhao^{3*}

**Correction to: *Journal for ImmunoTherapy of Cancer*
(2018) 6:101
Doi 10.1186/s40425-018-0421-z**

Following publication of the original article [1], the authors reported an error in their listed affiliations.

In this Correction Dr. Jiaxin Zhao is related to two affiliations:

1. The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
3. The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.

The published apologizes for any inconvenience caused by this error.

Received: 19 December 2018 Accepted: 19 December 2018
Published online: 11 January 2019

Reference

1. Zhao, et al. *Journal for ImmunoTherapy of Cancer*. 2018;6(101).
<https://doi.org/10.1186/s40425-018-0421-z>.

* Correspondence: doctorbinzhao@126.com; doctorhongzhao@126.com; doctorzhaojiaxin@163.com

¹The Second Affiliated Hospital & Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China

²The Third Affiliated Hospital of Harbin Medical University, Harbin, China

³The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China

